Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USA.
Hum Mol Genet. 2023 Aug 7;32(16):2646-2655. doi: 10.1093/hmg/ddad099.
Animal studies implicate one-carbon metabolism and DNA methylation genes in hepatocellular carcinoma (HCC) development in the setting of metabolic perturbations. Using human samples, we investigated the associations between common and rare variants in these closely related biochemical pathways and risk for metabolic HCC development in a multicenter international study. We performed targeted exome sequencing of 64 genes among 556 metabolic HCC cases and 643 cancer-free controls with metabolic conditions. Multivariable logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for multiple comparisons. Gene-burden tests were used for rare variant associations. Analyses were performed in the overall sample and among non-Hispanic whites. The results show that among non-Hispanic whites, presence of rare functional variants in ABCC2 was associated with 7-fold higher risk of metabolic HCC (OR = 6.92, 95% CI: 2.38-20.15, P = 0.0004), and this association remained significant when analyses were restricted to functional rare variants observed in ≥2 participants (cases 3.2% versus controls 0.0%, P = 1.02 × 10-5). In the overall multiethnic sample, presence of rare functional variants in ABCC2 was nominally associated with metabolic HCC (OR = 3.60, 95% CI: 1.52-8.58, P = 0.004), with similar nominal association when analyses were restricted to functional rare variants observed in ≥2 participants (cases 2.9% versus controls 0.2%, P = 0.006). A common variant in PNPLA3 (rs738409[G]) was associated with higher HCC risk in the overall sample (P = 6.36 × 10-6) and in non-Hispanic whites (P = 0.0002). Our findings indicate that rare functional variants in ABCC2 are associated with susceptibility to metabolic HCC in non-Hispanic whites. PNPLA3-rs738409 is also associated with metabolic HCC risk.
动物研究表明,在代谢紊乱的情况下,一碳代谢和 DNA 甲基化基因与肝细胞癌 (HCC) 的发展有关。在一项多中心国际研究中,我们使用人类样本,研究了这些密切相关的生化途径中的常见和罕见变异与代谢 HCC 发展风险之间的关联。我们对 556 例代谢性 HCC 病例和 643 例有代谢性疾病的无癌对照者的 64 个基因进行了靶向外显子测序。多变量逻辑回归用于计算比值比 (OR) 和 95%置信区间 (CI),并进行了多次比较调整。基因负担检验用于罕见变异关联。分析在总样本和非西班牙裔白人中进行。结果表明,在非西班牙裔白人中,ABCC2 中罕见功能变异的存在与代谢性 HCC 的 7 倍高风险相关 (OR=6.92,95%CI:2.38-20.15,P=0.0004),当分析仅限于≥2 名参与者中观察到的功能性罕见变异时,这种关联仍然显著 (病例 3.2%与对照 0.0%,P=1.02×10-5)。在多民族的总体样本中,ABCC2 中罕见功能变异的存在与代谢性 HCC 有显著的关联 (OR=3.60,95%CI:1.52-8.58,P=0.004),当分析仅限于≥2 名参与者中观察到的功能性罕见变异时,这种关联仍然显著 (病例 2.9%与对照 0.2%,P=0.006)。总体样本中,PNPLA3 中的常见变异 (rs738409[G]) 与 HCC 风险增加相关 (P=6.36×10-6),在非西班牙裔白人中也与 HCC 风险增加相关 (P=0.0002)。我们的研究结果表明,ABCC2 中的罕见功能变异与非西班牙裔白人群体中代谢性 HCC 的易感性有关。PNPLA3-rs738409 也与代谢性 HCC 风险相关。